STERIS plc (STE)

NYSE: STE · USD

$229

+0.05 (+0.0%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-09

Our latest published analysis: STE rated Hold

STERIS plc's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$210 / share

Potential value

$250 / share

Upside to FV

-2.3%

from $229

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$20.9B
Revenue (ttm)	6B
Net income (ttm)	805M
EPS (ttm)	$8.18
Shares out	97.5M
P/E (trailing)	27.9x
P/E (forward)	19.2x
Dividend	$2.76 (1.21%)
Volume	305,736
Beta	0.92

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 6B
Net income (ttm): 805M
EPS (ttm): $8.18
P/E (trailing): 27.9x
P/E (forward): 19.2x
Market cap: $20.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31	Trend
Revenue	$4.22B	$4.54B	$5.14B	$5.46B	$5.94B	+8.9%
Gross profit	$1.88B	$1.98B	$2.22B	$2.40B	$2.63B	+8.7%
Operating income	$477.8M	$791.1M	$836.1M	$866.6M	$1.10B	+23.2%
Net income	$243.9M	$107.0M	$378.2M	$614.6M	$782.3M	+33.8%
EPS (diluted)	$2.48	$1.07	$3.81	$6.20	$7.93	+33.7%
EBITDA	$1.01B	$1.36B	$1.41B	$1.36B	$1.59B	+12.1%
R&D	$86.7M	$98.5M	$103.7M	$107.6M	$112.9M	+6.8%
SG&A	$1.32B	$1.09B	$1.25B	$1.33B	$1.41B	+1.7%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base60%

Price target

$209.55

-2.3% from spot

The modal base case, carrying probability 60.0% and target $209.55 yielding an implied return of -2.3%, reflects steady execution across acute care hospital reprocessing and contract sterilization. STERIS delivers mid-to-high single-digit revenue growth while operating margins expand steadily toward target levels, balancing elevated near-term facility capex against durable cash generation.

Consolidated revenue growth tracking management guidance ranges across the explicit forecast horizon
Operating margins expanding steadily supported by operating cost discipline and favorable procedural mix
AST customer destocking subsiding in the second half of the fiscal year in line with management expectations
Capital expenditures normalizing toward maintenance requirements following greenfield facility completion

Bull20%

Price target

$249.66

+16.4% from spot

Under the bull case, with probability 20.0% and target $249.66 yielding an implied return of 16.4%, customer inventory destocking in contract sterilization resolves ahead of schedule while automated endoscope reprocessor share gains accelerate. Operating margins expand beyond historical peaks as the automated North Carolina facility ramps, driving double-digit operational earnings growth.

Accelerated recovery in AST organic volume throughput following customer destocking resolution
Rapid market share gains in automated endoscope reprocessors driving high-margin chemistry pull-through
Early operational efficiencies and labor savings from the automated greenfield facility consolidation
Complete tariff cost mitigation through commercial price increases and successful refund claims

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($209.55). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
8.0%	$218	$231	$247	$266	$290
8.5%	$203	$214	$226	$242	$260
9.0%	$190	$199	$210	$222	$237
9.5%	$179	$187	$195	$206	$218
10.0%	$169	$176	$183	$192	$202

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E19.2

P25 n/aP50 n/aP75 n/a

Trailing P/E25.8

P25 n/aP50 n/aP75 n/a

ROE11.4

P25 n/aP50 n/aP75 n/a

ROIC9.7

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All STE indicators

Market & fundamental data

Available fields

292

Groups with data

Currency

USD

Showing 292 of 292 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001757898
Company name	STERIS plc
Country	United States
Country code	US
CUSIP number	G8473T100
Earnings date	2026-11-04
Earnings time	amc
Employees	17,937
Employees change	150
Employees growth	0.84%
Enterprise value	$23.8B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	March
Founded	1985
In index	SP500
Industry	Medical Devices
IPO date	1992-06-01
Is primary listing	Yes
Is SPAC	No
ISIN number	IE00BFY8C754
Last 10-K release date	2026-05-29
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	1998-08-25
Last stock split type	Forward
Market cap	$22.3B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$228.54
Price currency	USD
Sector	Healthcare
SIC code	3842
Stock price date	2026-10-28
Symbol	STE
U.S. state	Ohio
Website	https://www.steris.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	21.93x
Average P/E ratio (10Y)	51.48x
Average P/E ratio (3Y)	40.47x
Average P/E ratio (5Y)	65.1x
Earnings yield	3.58%
EV/Earnings	29.76x
EV/EBIT	20.84x
EV/EBITDA	14.6x
EV/FCF	25.88x
EV/Sales	3.97x
FCF / EV yield	3.86%
FCF yield	4.13%
Forward EV/Sales	3.7x
Forward P/E	19.99x
Forward P/S	3.46x
Graham number	116.63846
Graham upside	-49.22%
Industry forward P/E	19.74x
Industry P/E	39.16x
Lynch fair value	$188.11
Lynch upside	-18.1%
P/(FCF - SBC) ratio	25.95x
P/(OCF - SBC) ratio	18.27x
P/B ratio	3.09x
P/E ratio	27.94x
P/FCF ratio	24.19x
P/OCF ratio	17.38x
P/S ratio	3.71x
Price / tangible book value	15.4x
Price/EBITDA ratio	13.65x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	19.04%
EBITDA margin	27.17%
Effective tax rate	25.79%
FCF margin	15.33%
Gross margin	44.42%
Operating margin	19.04%
Pretax margin	18.04%
Profit margin	13.33%
Profit per employee	$44,879
Profitable quarters	9
Profitable years	15
Revenue per employee	$336,595
ROA	6.8%
ROA (5Y)	5.39%
ROCE	12.16%
ROE	11.39%
ROE (5Y)	8.8%
ROIC	9.68%
ROIC (5Y)	7.95%
SBC / revenue	1.04%
Tax / revenue	4.65%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.29%
EPS growth (Q)	13.97%
EPS growth (QoQ)	-8.97%
EPS growth 10Y	16.73%
EPS growth 3Y	89.85%
EPS growth 5Y	20.07%
EPS growth quarters	9
EPS growth years	3
FCF growth	1.85%
FCF growth (Q)	-14.34%
FCF growth (QoQ)	14.03%
FCF growth 3Y	23.31%
FCF growth 5Y	16.89%
Gross profit growth	8.49%
Gross profit growth (Q)	8.95%
Gross profit growth 3Y	10.42%
Gross profit growth 5Y	12.73%
Net income growth	24.5%
Net income growth (Q)	12.8%
Net income growth (QoQ)	-9.13%
Net income growth 3Y	88.96%
Net income growth 5Y	22.99%
Net income growth quarters	9
Net income growth years	3
OCF growth	1.91%
OCF growth (Q)	-12.6%
OCF growth (QoQ)	9.45%
OCF growth 10Y	15.93%
OCF growth 3Y	16.91%
OCF growth 5Y	14.56%
Operating income growth	12.69%
Operating income growth (Q)	15.38%
Operating income growth 3Y	10.86%
Operating income growth 5Y	13.44%
Revenue growth	8.37%
Revenue growth (Q)	7.3%
Revenue growth (QoQ)	-6.02%
Revenue growth 10Y	9.52%
Revenue growth 3Y	9.78%
Revenue growth 5Y	12.12%
Revenue growth quarters	17
Revenue growth years	14

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-362.9M
Depreciation and amortization	$491M
EBIT	$1.1B
EBITDA	$1.6B
EPS	$8.18
FCF per share	$9.49
Financing cash flow	$-568.6M
Free cash flow	$925.6M
Free cash flow minus SBC	$863M
Gross profit	$2.7B
Income taxes	$280.8M
Investing cash flow	$-512.5M
Net borrowing	$-4.3M
Net cash flow	$202.6M
Net income	$805M
Operating cash flow minus SBC	$1.2B
Operating income	$1.1B
Revenue	$6B
Stock-based compensation	$62.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.44
Book value per share	$73.91
Debt / EBITDA	1.19
Debt / equity	0.28
Debt / FCF	2.21
Goodwill	$4.2B
Interest coverage	18.97
Long-term assets	$8.3B
Long-term liabilities	$2.2B
Net cash (debt)	$-1.6B
Net cash / market cap	-6.98%
Net debt / EBITDA	0.95
Net debt / equity	0.22
Net debt / FCF	1.69
Piotroski F-Score	7
Property, plant and equipment	$2.3B
Shareholders' equity	$7.2B
Tangible book value	$1.5B
Tangible book value per share	$14.91
Total assets	$10.7B
Total cash	$482.3M
Total debt	$2B
Total liabilities	$3.5B
WACC	8.74%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.57
Current assets	$2.4B
Current liabilities	$1.3B
Current ratio	1.91
Inventory turnover	4.96
Net working capital	$959.2M
Quick ratio	1.17
Working capital	$1.2B
Working capital turnover	5.26

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.48%
Dividend growth	10.26%
Dividend growth (10Y)	9.62%
Dividend growth (3Y)	10.16%
Dividend growth (5Y)	9.62%
Dividend growth years	15
Dividend payment date	2026-09-25
Dividend payment years	22
Dividend payout frequency	Quarterly
Dividend per share	$2.76
Dividend yield	1.21%
Ex-dividend date	2026-09-04
FCF payout ratio	29.07%
Last dividend	$0.69
Payout ratio	33.74%
Shareholder yield	1.69%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	241.8%
10Y return CAGR	14.28%
10Y total return	279.78%
150-day SMA	$218.50
15Y price change	609.02%
15Y return CAGR	15.44%
15Y total return	761.33%
1D price change	0.02%
1M price change	9.48%
1M total return	9.48%
1W price change	1.58%
1W total return	1.58%
1Y price change	-5.06%
1Y return CAGR	-4.01%
1Y total return	-4%
20-day SMA	$219.69
200-day SMA	$225.05
20Y price change	849.48%
20Y return CAGR	13.71%
20Y total return	1,206.8%
3M price change	4.73%
3M total return	5.05%
3Y price change	9.24%
3Y return CAGR	4.05%
3Y total return	12.64%
50-day SMA	$220.10
50-day SMA vs 200-day SMA	50under200
52-week high	$269.44
52-week high date	2026-01-16
52-week low	$195.14
52-week low date	2026-05-07
5Y price change	-1.46%
5Y return CAGR	0.68%
5Y total return	3.46%
6M price change	2.94%
6M total return	3.57%
All-time high	$269.44
All-time high date	2026-01-16
All-time low	$1.81
All-time low date	1992-06-01
Average true range (ATR)	$5.03
Average volume	686.7K
Beta (1Y)	0.14
Beta (2Y)	0.39
Beta (5Y)	0.92
Change from 52-week high	-15.18%
Change from 52-week low	17.12%
Change from all-time high	-15.11%
Change from all-time low	12,516.11%
Change from open	0.73%
Day's gap	-0.7%
Dollar volume	$69.9M
High price	$229.68
Low price	$226.88
Monthly RSI	50.2
Open price	$226.88
Position in 52-week range	59.29%
Premarket change	0%
Premarket close	$228.49
Premarket price	$228.50
Premarket volume	1.1K
Previous close	$228.49
Price vs 150-day SMA	4.68%
Price vs 20-day SMA	4.12%
Price vs 200-day SMA	1.64%
Price vs 50-day SMA	3.92%
Relative volume	0.45
RSI	62.05
Sharpe ratio	-0.18
Sharpe ratio (3Y)	0.08
Sharpe ratio (5Y)	0.02
Sortino ratio	-0.04
Sortino ratio (3Y)	0.38
Sortino ratio (5Y)	0.25
Volume	305.7K
Weekly RSI	53.5
YTD price change	-9.78%
YTD total return	-9%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	97.1M
Float percentage	99.57%
Shares change (QoQ)	-0.51%
Shares change (YoY)	-0.48%
Shares held by insiders	0.33%
Shares held by institutions	100.17%
Shares outstanding	97.5M
Short % of float	2.94%
Short % of shares	2.93%
Short ratio	4.3 days

Deeper analysis on STE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this STE report

What is the latest published STE stock rating?

STERIS plc is shown with Hold in the latest published report, analyzed 2026-10-09. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full STE analysis?

The full latest published report, analyzed 2026-10-09, lives at /stocks/STE/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for STE?

The latest published report analyzed 2026-10-09 gives STE a fair value of USD 210 and a potential value of USD 250. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the STE page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-09). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldSTE · Fair value $210-2.3%

Read full analysis →

Category	Score	Reading
Valuation	4.5
Management	8.5
Balance Sheet	8.0
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	7.5
Competitive Moat	9.0
Earnings Quality	8.0
Capital Efficiency	5.5

STERIS plc (STE)

Our latest published analysis: STE rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · STE

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All STE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on STE

Frequently asked questions

评级历史